Jun. 24 at 3:46 PM
$AXSM $AXSM path to
$375 over the next 12 months looks realistic. Auvelity continues to scale in MDD, Alzheimer’s agitation adds a major approved market, AXS-12 has already been submitted, and solriamfetol has important Phase 3 data ahead. Sunosi and Symbravo add commercial depth, while foreign rights still appear under-monetized. With long-term peak sales potential estimated above
$16B, a
$375 share price would still not fully reflect the value of the broader CNS platform. The stock does not need perfection to get there. It needs continued script growth, ADA launch traction, and a clearer path toward operating leverage. If AXSM moves toward a
$1.5B to
$1.8B annualized revenue run rate,
$375 becomes a rational valuation target.
